CRISPR (CRSP) Gains Analyst Support on Sales Momentum and Pipeline Expansion

CRISPR Therapeutics AG (NASDAQ:CRSP) is one of the best emerging technology stocks to buy right now. On September 3, Bank of America Securities analyst Alec Stranahan reiterated a Buy rating on CRISPR Therapeutics AG (NASDAQ:CRSP) with an unchanged price target of $78. The rating comes as the company continues to advance its CRISPR/Cas9 gene-editing platform, a breakthrough technology for gene editing that enables precise changes to DNA sequences and directly corrects faulty genes. With a pipeline that sp ...